FULCRUM THERAPEUTICS INC
FULCNASDAQTrading Snapshot
- Day Range
- $3.65 β $3.71
- 52-Week Range
- $2.83 β $15.74
- Volume
- $2.42B
- Avg Volume
- $3.15B
- Shares Outstanding
- 66.6M
- Next Earnings
- Oct 27, 2026
Fundamentals Snapshot
- Annual Revenue
- $81M
- Last Q Revenue
- $22M
- P/E Ratio
- β
- P/S Ratio
- 3.5x
- EPS (TTM)
- $-0.90
- Dividend Yield
- β
Why Investors Own FULC
- βHigh-growth profile β revenue up +53.6% YoY with expanding US Equity exposure.
- βHealthy economics β 40% gross margin and 16% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About FULCRUM THERAPEUTICS INC
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
Otter Score Breakdown
βAnalyst Ratings
βLatest News & Updates
Fulcrum Therapeutics (FULC) Stock Sees Modest Fair Value Lift After Pociredir Exit
The updated analyst framework for Fulcrum Therapeutics lifts the Fair Value estimate from US$5.43 to US$5.83 per share. This shift in price target sits against a backdrop of sharply changed Street commentary after the decision to discontinue pociredir, with more focus on cash, restructuring and the ongoing review of options than on late stage development potential. Read on to see how this evolving narrative could matter for your own view on Fulcrum Therapeutics and how to track the next set...
Fulcrum Therapeutics: Buy It For The Strategic Reset
Fulcrum trades below NCAV amid operational distress but boasts a fortress balance sheetΓ’ΒΒexplore why this deep-discount setup could outperform.